Megovalicin B
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-02316 |
| CAS | 89759-26-2 |
| Molecular Weight | 621.85 |
| Molecular Formula | C35H59NO8 |
Online Inquiry
Description
It is produced by the strain of Myxococcus flavescens No. 154. It has the effect against subtilis and Escherichia coli. Megovalicin H shows the strongest antibacterial activity among the 6 components.
Specification
| Synonyms | Myxovirescin B; 1-Oxa-4-azacyclooctacosa-12,14,26-triene-3,20,28-trione,16-ethyl-6,8,9-trihydroxy-12-(methoxymethyl)-25,27-dimethyl-2-propyl-, (2S,6S,8S,9R,12Z,14E,16R,25R,26E)-; Myxovirescin A1, 2,3-didehydro-; 1-Oxa-4-azacyclooctacosa-12,14,26-triene-3,20,28-trione,16-ethyl-6,8,9-trihydroxy-12-(methoxymethyl)-25,27-dimethyl-2-propyl-, [2S-(2R*,6R*,8R*,9S*,12Z,14E,16S*,25S*,26E)]-; Antibiotic M 230B |
| IUPAC Name | (2S,6S,8S,9R,12E,14Z,16R,25R,26Z)-16-ethyl-6,8,9-trihydroxy-12-(methoxymethyl)-25,27-dimethyl-2-propyl-1-oxa-4-azacyclooctacosa-12,14,26-triene-3,20,28-trione |
| Canonical SMILES | CCCC1C(=O)NCC(CC(C(CCC(=CC=CC(CCCC(=O)CCCCC(C=C(C(=O)O1)C)C)CC)COC)O)O)O |
| InChI | InChI=1S/C35H59NO8/c1-6-12-33-34(41)36-23-30(38)22-32(40)31(39)20-19-28(24-43-5)16-10-14-27(7-2)15-11-18-29(37)17-9-8-13-25(3)21-26(4)35(42)44-33/h10,14,16,21,25,27,30-33,38-40H,6-9,11-13,15,17-20,22-24H2,1-5H3,(H,36,41)/b14-10-,26-21-,28-16+/t25-,27+,30+,31-,32+,33+/m1/s1 |
| InChI Key | CANOHYLGAOUVMU-XBKRHCJASA-N |
Properties
| Antibiotic Activity Spectrum | Gram-positive bacteria; Gram-negative bacteria |
| Melting Point | 109-111°C |
| Solubility | Soluble in Methanol |
Reference Reading
1. Hepatitis B Vaccines
Jade Pattyn, Greet Hendrickx, Alex Vorsters, Pierre Van Damme J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S343-S351. doi: 10.1093/infdis/jiaa668.
Hepatitis B is caused by the hepatitis B virus (HBV), which infects the liver and may lead to chronic liver disease, including cirrhosis and hepatocellular carcinoma. HBV represents a worldwide public health problem, causing major morbidity and mortality. Affordable, safe, and effective, hepatitis B vaccines are the best tools we have to control and prevent hepatitis B. In 2019, coverage of 3 doses of the hepatitis B vaccine reached 85% worldwide compared to around 30% in 2000. The effective implementation of hepatitis B vaccination programs has resulted in a substantial decrease in the HBV carrier rate and hepatitis B-related morbidity and mortality. This article summarizes the great triumphs of the hepatitis B vaccine, the first anticancer and virus-like-particle-based vaccine. In addition, existing unresolved issues and future perspectives on hepatitis B vaccination required for global prevention of HBV infection are discussed.
2. Hepatitis B Virus: From Diagnosis to Treatment
Meryem Guvenir, Ayse Arikan Pol J Microbiol. 2020 Dec;69(4):391-399. doi: 10.33073/pjm-2020-044. Epub 2020 Dec 27.
Hepatitis B infection is still a global concern progressing as acute-chronic hepatitis, severe liver failure, and death. The infection is most widely transmitted from the infected mother to a child, with infected blood and body fluids. Pregnant women, adolescents, and all adults at high risk of chronic infection are recommended to be screened for hepatitis B infection. The initial analysis includes serological tests that allow differentiation of acute and chronic hepatitis. Molecular assays performed provide detection and quantification of viral DNA, genotyping, drug resistance, and precore/core mutation analysis to confirm infection and monitor disease progression in chronic hepatitis B patients. All patients with chronic hepatitis B should be treated with antiviral medications and regularly monitored for efficient treatment. The current treatment is based on nucleos(t)ide analogs and pegylated interferons that save lives by decreasing liver cancer death, liver transplant, slow or reverse the progression of liver disease as well as the virus infectivity.
3. The four novel HLA-B alleles in unrelated Russian individuals: HLA-B*38:01:18, -B*39:01:28, -B*40:484, -B*44:498
Anastasiia Ananeva, Iuliia Sergeeva, Elena Shagimardanova HLA. 2022 Jan;99(1):42-44. doi: 10.1111/tan.14449. Epub 2021 Oct 14.
Four new HLA-B alleles, B*38:01:18, B*39:01:28, B*40:484, and B*44:498, alleles detected in Russian individuals.
Recommended Products
| BBF-01825 | Loganin | Inquiry |
| BBF-04301 | Tulathromycin A | Inquiry |
| BBF-03211 | AT-265 | Inquiry |
| BBF-03963 | Pristinamycin | Inquiry |
| BBF-05817 | Astaxanthin | Inquiry |
| BBF-02576 | Pneumocandin B0 | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
